EN | JPN | FR

Our Leadership Team

matt chapin portrait

Matt Chapin

Senior Vice President, Ora Asset Development & Partnering

Matt Chapin a Senior Vice President and Partner in Ora’s Asset Development & Partnering group. In his role Matt supports early entrepreneurs, start-ups, bio-tech, pharma companies, and investors, for financing, licensing, program diligence, development planning, and project strategy. Matt supports and co-leads strategic relationships with client partners including structure and management of risk sharing and co-development programs. For the past 23+ years, Matt has held positions within Ora across clinical and preclinical research and development, product strategy, writing, regulatory, development program management, marketing and business development. Matt has helped multiple large pharma and small virtual start-ups transition from preclinical through pre-IND strategy, FDA meetings, and IND/Phase 2, leading the preparation/submission and representation at FDA for many regulatory meetings. Matt serves on the advisory board of Infocus Capital, an ophthalmology dedicated venture fund, (http://infocuscapitalpartners.com/), as well as providing other board and joint development committee representation for Ora partners. Matt has contributed to numerous publications in peer-review, trade journals, book chapters, and conference presentations, and is co-inventor on multiple patents and patent applications. Matt contributes a quarterly column in the publication Review of Ophthalmology- Ophthalmic Product Development Insights, and serves as a judge for The Winning Pitch Challenge at the American Society of Retina Surgeons (ASRS) (http://winningpitchchallenge.net/).

We partner with industry-leading companies to create vision beyond what we see.

regeneron logo
alltergan logo
regentree logo
mallinkrodt logo
stealth logo
nicox logo
astellas logo
canon logo
rayner logo

For over 45+ years, Ora has been on the leading edge of ophthalmic product development.

When your product shows promise, let's prove it.